Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

Comment by jopatcloon Aug 27, 2024 9:44am
59 Views
Post# 36197471

RE: Health Canada has approved 👏us, FDA won’t be far behind 🚀

RE: Health Canada has approved đź‘Źus, FDA won’t be far behind 🚀Interesting for Ventripoint https://www.asecho.org/echoinpchd/
Coming October 26-27, our 3rd Annual Echo in PCHD will present the latest information on established and emerging cardiovascular ultrasound technologies, clinical care and practical considerations in patients with CHD. bit.ly/3yR7NXg

There will be dedicated Q&A times where faculty will be live to answer questions.

Course Chairs:
Melissa Wasserman
, RDCS, RCCS, FASE
Shiraz Maskatia
, MD, FASE

Echo in Pediatric and Congenital Heart Disease Virtual Experience

The 3rd Annual Echo in Pediatric and Congenital Heart Disease is a two-day virtual course, presenting the latest information on established and emerging cardiovascular ultrasound technologies, clinical care and practical considerationsin children and adults with congenital heart disease. Expert physician and sonographer faculty discuss current technologies with a particular focus on how they can be effectively applied in the clinical setting.

Topics include:

  • What’s New In The Guidelines?
  • PCHD From Around the World
  • Investigating Echo in CHD
  • Is Echo Enough? Multi-Modality Imaging – Debate & Talk
  • Fetal Cardiology Cases: Torture the Experts!
  • Imaging ACHD from the Sonographer’s Perspective
  • 3D For Everything
  • Career Development Roundtable: How Organizations Can Enhance My Echo Career

All sessions will have dedicated Question and Answer time where faculty will be joining live to answer participantquestions.

Learning Objectives

At the end of this course, that participant will be able to:

  • Describe imaging goals and approaches to a variety of challenging forms of congenital heart disease, from infancy to adulthood.
  • Understand and apply current techniques in imaging assessment of cardiac anatomy and function, including contrast imaging in pediatrics, advanced 3D echo, myocardial work and CRT in children.
  • Apply techniques to promote well-being, resiliency, and career advancement of your entire sonographer team.

jopatclo wrote: Great comment from Miro Cernetig on Linkedin from Hugh's repost (A.I. is going to vastly improve health care for everyone. One application, now in use, is Ventripoint. It turns ultrasounds of the heart into detailed images that are created in a fraction of the time and cost of using an MRI. It's of real importance in the treatment of infants and children with heart conditions. is a great made-in-Canada technology now being used in hospitals in Canada, the U.S., U.K. and Europe)

post Hugh (Yesterday I had the pleasure working with our Clinical Applications Manager Cristina Almeida during her upgrade of the system at the Seattle Children's Hospital to the new magnet-less sensors. It was a great opportunity to visit a customer site, observe and learn about their clinical environment and workflows, and discuss future development plans.) and now remember health Canada has approved us, FDA won’t be far behind. The visionary Dr. G. Adams and Alvira M. have done the long work that had to be done during all these years for Ventripoint to arrive V4.0 Bravo procurement in healthcare is complex . FDA V4.0 and Sales at any time now Insiders know!


<< Previous
Bullboard Posts
Next >>